{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T10:45:21Z","timestamp":1794221121110,"version":"4.8.0"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T00:00:00Z","timestamp":1624924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T00:00:00Z","timestamp":1624924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1038\/s41584-021-00634-x","type":"journal-article","created":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T13:02:53Z","timestamp":1624971773000},"page":"475-486","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":153,"title":["Current and future therapies for primary Sj\u00f6gren syndrome"],"prefix":"10.1038","volume":"17","author":[{"given":"Rapha\u00e8le","family":"Seror","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetane","family":"Nocturne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4244-5417","authenticated-orcid":false,"given":"Xavier","family":"Mariette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,29]]},"reference":[{"key":"634_CR1","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/MD.0b013e318181e6af","volume":"87","author":"M Ramos-Casals","year":"2008","unstructured":"Ramos-Casals, M. et al. Primary Sj\u00f6gren syndrome in Spain: clinical and immunologic expression in 1010\u00a0patients. Medicine 87, 210\u2013219 (2008).","journal-title":"Medicine"},{"key":"634_CR2","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1056\/NEJMcp1702514","volume":"378","author":"X Mariette","year":"2018","unstructured":"Mariette, X. & Criswell, L. A. Primary Sj\u00f6gren\u2019s syndrome. N. Engl. J. Med. 378, 931\u2013939 (2018).","journal-title":"N. Engl. J. Med."},{"key":"634_CR3","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nrrheum.2013.110","volume":"9","author":"G Nocturne","year":"2013","unstructured":"Nocturne, G. & Mariette, X. Advances in understanding the pathogenesis of primary Sj\u00f6gren\u2019s syndrome. Nat. Rev. Rheumatol. 9, 544\u2013556 (2013).","journal-title":"Nat. Rev. Rheumatol."},{"key":"634_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2019-216114","volume":"79","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals, M. et al. EULAR recommendations for the management of Sj\u00f6gren\u2019s syndrome with topical and systemic therapies. Ann. Rheum. Dis. 79, 3\u201318 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"634_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001064","volume":"5","author":"P Brito-Zer\u00f3n","year":"2019","unstructured":"Brito-Zer\u00f3n, P. et al. Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sj\u00f6gren\u2019s syndrome. RMD Open 5, e001064 (2019).","journal-title":"RMD Open"},{"key":"634_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0143970","volume":"10","author":"K James","year":"2015","unstructured":"James, K. et al. A transcriptional signature of fatigue derived from patients with primary Sj\u00f6gren\u2019s syndrome. PLoS ONE 10, e0143970 (2015).","journal-title":"PLoS ONE"},{"key":"634_CR7","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1136\/ard.2004.030643","volume":"64","author":"J-E Gottenberg","year":"2005","unstructured":"Gottenberg, J.-E. et al. Correlation of serum B lymphocyte stimulator and \u03b22 microglobulin with autoantibody secretion and systemic involvement in primary Sjogren\u2019s syndrome. Ann. Rheum. Dis. 64, 1050\u20131055 (2005).","journal-title":"Ann. Rheum. Dis."},{"key":"634_CR8","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1002\/art.39518","volume":"68","author":"G Nocturne","year":"2016","unstructured":"Nocturne, G. et al. Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sj\u00f6gren\u2019s syndrome. Arthritis Rheumatol. 68, 977\u2013985 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"634_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez052","author":"G Nocturne","year":"2019","unstructured":"Nocturne, G., Pontarini, E., Bombardieri, M. & Mariette, X. Lymphomas complicating primary Sj\u00f6gren\u2019s syndrome: from autoimmunity to lymphoma. Rheumatology https:\/\/doi.org\/10.1093\/rheumatology\/kez052 (2019).","journal-title":"Rheumatology"},{"key":"634_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116189","volume":"10","author":"A Papageorgiou","year":"2015","unstructured":"Papageorgiou, A. et al. Predicting the outcome of Sjogren\u2019s syndrome-associated non-Hodgkin\u2019s lymphoma patients. PLoS ONE 10, e0116189 (2015).","journal-title":"PLoS ONE"},{"key":"634_CR11","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/bjh.13192","volume":"168","author":"G Nocturne","year":"2015","unstructured":"Nocturne, G. & Mariette, X. Sj\u00f6gren syndrome-associated lymphomas: an update on pathogenesis and management. Br. J. Haematol. 168, 317\u2013327 (2015).","journal-title":"Br. J. Haematol."},{"key":"634_CR12","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrrheum.2018.1","volume":"14","author":"G Nocturne","year":"2018","unstructured":"Nocturne, G. & Mariette, X. B cells in the pathogenesis of primary Sj\u00f6gren syndrome. Nat. Rev. Rheumatol. 14, 133\u2013145 (2018).","journal-title":"Nat. Rev. Rheumatol."},{"key":"634_CR13","doi-asserted-by":"publisher","first-page":"233","DOI":"10.7326\/M13-1085","volume":"160","author":"V Devauchelle-Pensec","year":"2014","unstructured":"Devauchelle-Pensec, V. et al. Treatment of primary Sj\u00f6gren syndrome with rituximab: a randomized trial. Ann. Intern. Med. 160, 233\u2013242 (2014).","journal-title":"Ann. Intern. Med."},{"key":"634_CR14","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1002\/art.40093","volume":"69","author":"SJ Bowman","year":"2017","unstructured":"Bowman, S. J. et al. Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sj\u00f6gren\u2019s syndrome. Arthritis Rheumatol. 69, 1440\u20131450 (2017).","journal-title":"Arthritis Rheumatol."},{"issue":"suppl. 126","key":"634_CR15","first-page":"10","volume":"38","author":"V Manfr\u00e8","year":"2020","unstructured":"Manfr\u00e8, V. et al. One year in review 2020: comorbidities, diagnosis and treatment of primary Sj\u00f6gren\u2019s syndrome. Clin. Exp. Rheumatol. 38 (Suppl. 126), 10\u201322 (2020).","journal-title":"Clin. Exp. Rheumatol."},{"key":"634_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1136\/annrheumdis-2016-210571","volume":"76","author":"CH Shiboski","year":"2017","unstructured":"Shiboski, C. H. et al. 2016 American College of Rheumatology\/European League Against Rheumatism classification criteria for primary Sj\u00f6gren\u2019s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Ann. Rheum. Dis. 76, 9\u201316 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"634_CR17","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1002\/acr.21991","volume":"65","author":"R Seror","year":"2013","unstructured":"Seror, R. et al. European League Against Rheumatism Sj\u00f6gren\u2019s Syndrome Disease Activity Index and European League Against Rheumatism Sj\u00f6gren\u2019s Syndrome Patient-Reported Index: a complete picture of primary Sj\u00f6gren\u2019s syndrome patients. Arthritis Care Res. 65, 1358\u20131364 (2013).","journal-title":"Arthritis Care Res."},{"key":"634_CR18","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1136\/annrheumdis-2014-206008","volume":"75","author":"R Seror","year":"2016","unstructured":"Seror, R. et al. Defining disease activity states and clinically meaningful improvement in primary Sj\u00f6gren\u2019s syndrome with EULAR primary Sj\u00f6gren\u2019s syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann. Rheum. Dis. 75, 382\u2013389 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"634_CR19","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/acr.20173","volume":"62","author":"R Seror","year":"2010","unstructured":"Seror, R. et al. Accurate detection of changes in disease activity in primary Sj\u00f6gren\u2019s syndrome by the European League Against Rheumatism Sj\u00f6gren\u2019s Syndrome Disease Activity Index. Arthritis Care Res. 62, 551\u2013558 (2010).","journal-title":"Arthritis Care Res."},{"key":"634_CR20","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1136\/annrheumdis-2013-204615","volume":"74","author":"R Seror","year":"2015","unstructured":"Seror, R. et al. Validation of EULAR primary Sj\u00f6gren\u2019s syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Ann. Rheum. Dis. 74, 859\u2013866 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"634_CR21","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1136\/annrheumdis-2012-202293","volume":"72","author":"J-E Gottenberg","year":"2013","unstructured":"Gottenberg, J.-E. et al. Efficacy of rituximab in systemic manifestations of primary Sjogren\u2019s syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Ann. Rheum. Dis. 72, 1026\u20131031 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"634_CR22","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1136\/ard.2011.153098","volume":"70","author":"M Pertovaara","year":"2011","unstructured":"Pertovaara, M. & Korpela, M. Serum \u03b22 microglobulin correlates with the new ESSDAI in patients with Sj\u00f6gren\u2019s syndrome. Ann. Rheum. Dis. 70, 2236\u20132237 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"634_CR23","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/rheumatology\/kes180","volume":"52","author":"L Quartuccio","year":"2013","unstructured":"Quartuccio, L. et al. BLyS upregulation in Sjogren\u2019s syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. Rheumatology 52, 276\u2013281 (2013).","journal-title":"Rheumatology"},{"key":"634_CR24","doi-asserted-by":"publisher","first-page":"3218","DOI":"10.1002\/art.38129","volume":"65","author":"GJ Tob\u00f3n","year":"2013","unstructured":"Tob\u00f3n, G. J. et al. Role of Fms-like tyrosine kinase 3 ligand as a potential biologic marker of lymphoma in primary Sj\u00f6gren\u2019s syndrome. Arthritis Rheum. 65, 3218\u20133227 (2013).","journal-title":"Arthritis Rheum."},{"key":"634_CR25","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1136\/annrheumdis-2014-206418","volume":"75","author":"P Brito-Zer\u00f3n","year":"2016","unstructured":"Brito-Zer\u00f3n, P. et al. Systemic activity and mortality in primary Sj\u00f6gren syndrome: predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients. Ann. Rheum. Dis. 75, 348\u2013355 (2016).","journal-title":"Ann. Rheum. Dis."},{"issue":"Suppl. 112","key":"634_CR26","first-page":"121","volume":"36","author":"A Flores-Ch\u00e1vez","year":"2018","unstructured":"Flores-Ch\u00e1vez, A. et al. Severe, life-threatening phenotype of primary Sj\u00f6gren\u2019s syndrome: clinical characterisation and outcomes in 1580 patients (GEAS-SS Registry). Clin. Exp. Rheumatol. 36 (Suppl. 112), 121\u2013129 (2018).","journal-title":"Clin. Exp. Rheumatol."},{"key":"634_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059868","volume":"8","author":"J-E Gottenberg","year":"2013","unstructured":"Gottenberg, J.-E. et al. Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sj\u00f6gren\u2019s syndrome. Data at enrollment in the prospective ASSESS cohort. PLoS ONE 8, e59868 (2013).","journal-title":"PLoS ONE"},{"key":"634_CR28","doi-asserted-by":"publisher","first-page":"R155","DOI":"10.1186\/ar3895","volume":"14","author":"K Sacre","year":"2012","unstructured":"Sacre, K., Criswell, L. A. & McCune, J. M. Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Res. Ther. 14, R155 (2012).","journal-title":"Arthritis Res. Ther."},{"key":"634_CR29","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jama.2014.7682","volume":"312","author":"J-E Gottenberg","year":"2014","unstructured":"Gottenberg, J.-E. et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sj\u00f6gren syndrome: the JOQUER randomized clinical trial. JAMA 312, 249\u2013258 (2014).","journal-title":"JAMA"},{"issue":"Suppl. 1","key":"634_CR30","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1177\/0961203396005001081","volume":"5","author":"RI Fox","year":"1996","unstructured":"Fox, R. I., Dixon, R., Guarrasi, V. & Krubel, S. Treatment of primary Sj\u00f6gren\u2019s syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus 5 (Suppl. 1), S31\u2013S36 (1996).","journal-title":"Lupus"},{"key":"634_CR31","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1136\/ard.58.4.253","volume":"58","author":"M Tishler","year":"1999","unstructured":"Tishler, M., Yaron, I., Shirazi, I. & Yaron, M. Hydroxychloroquine treatment for primary Sj\u00f6gren\u2019s syndrome: its effect on salivary and serum inflammatory markers. Ann. Rheum. Dis. 58, 253\u2013256 (1999).","journal-title":"Ann. Rheum. Dis."},{"key":"634_CR32","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1136\/ard.52.5.360","volume":"52","author":"AA Kruize","year":"1993","unstructured":"Kruize, A. A. et al. Hydroxychloroquine treatment for primary Sj\u00f6gren\u2019s syndrome: a two year double blind crossover trial. Ann. Rheum. Dis. 52, 360\u2013364 (1993).","journal-title":"Ann. Rheum. Dis."},{"key":"634_CR33","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/rheumatology\/kez242","volume":"59","author":"ILA Bodewes","year":"2020","unstructured":"Bodewes, I. L. A., Gottenberg, J.-E., van\u00a0Helden-Meeuwsen, C. G., Mariette, X. & Versnel,\u00a0M. A. Hydroxychloroquine treatment downregulates systemic interferon activation in primary Sj\u00f6gren\u2019s syndrome in the JOQUER randomized trial. Rheumatology 59, 107\u2013111 (2020).","journal-title":"Rheumatology"},{"key":"634_CR34","doi-asserted-by":"publisher","first-page":"e260","DOI":"10.1016\/S2665-9913(20)30057-6","volume":"2","author":"EHM van der Heijden","year":"2020","unstructured":"van der Heijden, E. H. M. et al. Leflunomide\u2013hydroxychloroquine combination therapy in patients with primary Sj\u00f6gren\u2019s syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial. Lancet Rheumatol. 2, e260\u2013e269 (2020).","journal-title":"Lancet Rheumatol."},{"key":"634_CR35","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1002\/art.20146","volume":"50","author":"X Mariette","year":"2004","unstructured":"Mariette, X. et al. Inefficacy of infliximab in primary Sj\u00f6gren\u2019s syndrome: results of the randomized, controlled trial of remicade in primary Sj\u00f6gren\u2019s syndrome (TRIPSS). Arthritis Rheum. 50, 1270\u20131276 (2004).","journal-title":"Arthritis Rheum."},{"key":"634_CR36","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1002\/art.20299","volume":"50","author":"V Sankar","year":"2004","unstructured":"Sankar, V. et al. Etanercept in Sj\u00f6gren\u2019s syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum. 50, 2240\u20132245 (2004).","journal-title":"Arthritis Rheum."},{"key":"634_CR37","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1073\/pnas.0408506102","volume":"102","author":"AK Palucka","year":"2005","unstructured":"Palucka, A. K., Blanck, J.-P., Bennett, L., Pascual, V. & Banchereau, J. Cross-regulation of TNF and IFN-\u03b1 in autoimmune diseases. Proc. Natl Acad. Sci. USA 102, 3372\u20133377 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"634_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030123","volume":"7","author":"KB Norheim","year":"2012","unstructured":"Norheim, K. B., Harboe, E., G\u00f8ransson, L. G. & Omdal, R. Interleukin-1 inhibition and fatigue in primary Sj\u00f6gren\u2019s syndrome\u2014a double blind, randomised clinical trial. PLoS ONE 7, e30123 (2012).","journal-title":"PLoS ONE"},{"key":"634_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000282","volume":"2","author":"N Howard Tripp","year":"2016","unstructured":"Howard Tripp, N. et al. Fatigue in primary Sj\u00f6gren\u2019s syndrome is associated with lower levels of proinflammatory cytokines. RMD Open 2, e000282 (2016).","journal-title":"RMD Open"},{"key":"634_CR40","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1002\/art.21260","volume":"52","author":"J Pijpe","year":"2005","unstructured":"Pijpe, J. et al. Rituximab treatment in patients with primary Sj\u00f6gren\u2019s syndrome: an open-label phase II study. Arthritis Rheum. 52, 2740\u20132750 (2005).","journal-title":"Arthritis Rheum."},{"key":"634_CR41","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/art.22536","volume":"57","author":"V Devauchelle-Pensec","year":"2007","unstructured":"Devauchelle-Pensec, V. et al. Improvement of Sj\u00f6gren\u2019s syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum. 57, 310\u2013317 (2007).","journal-title":"Arthritis Rheum."},{"key":"634_CR42","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/art.37850","volume":"65","author":"EW St Clair","year":"2013","unstructured":"St Clair, E. W. et al. Rituximab therapy for primary Sj\u00f6gren\u2019s syndrome: an open-label clinical trial and mechanistic analysis. Arthritis Rheum. 65, 1097\u20131106 (2013).","journal-title":"Arthritis Rheum."},{"key":"634_CR43","first-page":"6","volume":"29","author":"V Devauchelle-Pensec","year":"2011","unstructured":"Devauchelle-Pensec, V. et al. Effects of rituximab therapy on quality of life in patients with primary Sj\u00f6gren\u2019s syndrome. Clin. Exp. Rheumatol. 29, 6\u201312 (2011).","journal-title":"Clin. Exp. Rheumatol."},{"key":"634_CR44","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1093\/rheumatology\/kep141","volume":"48","author":"JM Meijer","year":"2009","unstructured":"Meijer, J. M. et al. Health-related quality of life, employment and disability in patients with Sjogren\u2019s\u00a0syndrome. Rheumatology 48, 1077\u20131082 (2009).","journal-title":"Rheumatology"},{"key":"634_CR45","doi-asserted-by":"publisher","first-page":"R172","DOI":"10.1186\/ar4359","volume":"15","author":"F Carubbi","year":"2013","unstructured":"Carubbi, F. et al. Efficacy and safety of rituximab treatment in early primary Sj\u00f6gren\u2019s syndrome: a prospective, multi-center, follow-up study. Arthritis Res. Ther. 15, R172 (2013).","journal-title":"Arthritis Res. Ther."},{"key":"634_CR46","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/ard.2006.057919","volume":"66","author":"R Seror","year":"2007","unstructured":"Seror, R. et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sj\u00f6gren\u2019s syndrome. Ann. Rheum. Dis. 66, 351\u2013357 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"634_CR47","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1136\/annrheumdis-2011-200086","volume":"71","author":"A Mekinian","year":"2012","unstructured":"Mekinian, A. et al. Efficacy of rituximab in primary Sjogren\u2019s syndrome with peripheral nervous system involvement: results from the AIR registry. Ann. Rheum. Dis. 71, 84\u201387 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"634_CR48","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1136\/ard.2007.083865","volume":"67","author":"S Dass","year":"2008","unstructured":"Dass, S. et al. Reduction of fatigue in Sj\u00f6gren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann. Rheum. Dis. 67, 1541\u20131544 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"634_CR49","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1002\/art.27314","volume":"62","author":"JM Meijer","year":"2010","unstructured":"Meijer, J. M. et al. Effectiveness of rituximab treatment in primary Sj\u00f6gren\u2019s syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 62, 960\u2013968 (2010).","journal-title":"Arthritis Rheum."},{"key":"634_CR50","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1136\/annrheumdis-2013-203991","volume":"74","author":"X Mariette","year":"2015","unstructured":"Mariette, X. et al. Efficacy and safety of belimumab in primary Sj\u00f6gren\u2019s syndrome: results of the BELISS open-label phase II study. Ann. Rheum. Dis. 74, 526\u2013531 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"634_CR51","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/324073a0","volume":"324","author":"T Hirano","year":"1986","unstructured":"Hirano, T. et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324, 73\u201376 (1986).","journal-title":"Nature"},{"key":"634_CR52","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1046\/j.1365-3083.1999.00533.x","volume":"49","author":"A Halse","year":"1999","unstructured":"Halse, A., Tengn\u00e9r, P., Wahren-Herlenius, M., Haga, H. & Jonsson, R. Increased frequency of cells secreting interleukin-6 and interleukin-10 in peripheral blood of patients with primary Sj\u00f6gren\u2019s syndrome. Scand. J. Immunol. 49, 533\u2013538 (1999).","journal-title":"Scand. J. Immunol."},{"key":"634_CR53","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1016\/S0161-6420(98)91236-2","volume":"105","author":"M Tishler","year":"1998","unstructured":"Tishler, M. et al. Elevated tear interleukin-6 levels in patients with Sj\u00f6gren syndrome. Ophthalmology 105, 2327\u20132329 (1998).","journal-title":"Ophthalmology"},{"key":"634_CR54","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1136\/annrheumdis-2020-218467","volume":"80","author":"R Felten","year":"2021","unstructured":"Felten, R. et al. Interleukin 6 receptor inhibition in primary Sj\u00f6gren syndrome: a multicentre double-blind randomised placebo-controlled trial. Ann. Rheum. Dis. 80, 329\u2013338 (2021).","journal-title":"Ann. Rheum. Dis."},{"issue":"suppl. 10","key":"634_CR55","first-page":"988","volume":"72","author":"R Furie","year":"2020","unstructured":"Furie, R. et al. Two-year results from a randomized, controlled study of obinutuzumab for proliferative lupus nephritis [abstract]. Arthritis Rheumatol. 72 (Suppl. 10), 988 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"634_CR56","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/j.1365-3083.2007.02049.x","volume":"67","author":"F Lavie","year":"2008","unstructured":"Lavie, F. et al. B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sj\u00f6gren\u2019s syndrome. Scand. J. Immunol. 67, 185\u2013192 (2008).","journal-title":"Scand. J. Immunol."},{"key":"634_CR57","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1136\/annrheumdis-2012-202071","volume":"72","author":"RPE Pollard","year":"2013","unstructured":"Pollard, R. P. E. et al. Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren\u2019s syndrome: data from a placebo-controlled clinical trial. Ann. Rheum. Dis. 72, 146\u2013148 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"634_CR58","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jaut.2015.11.002","volume":"67","author":"D Cornec","year":"2016","unstructured":"Cornec, D. et al. Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sj\u00f6gren\u2019s syndrome. J. Autoimmun. 67, 102\u2013110 (2016).","journal-title":"J. Autoimmun."},{"key":"634_CR59","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/art.41466","volume":"73","author":"Y Atisha-Fregoso","year":"2021","unstructured":"Atisha-Fregoso, Y. et al. Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis. Arthritis Rheumatol. 73, 121\u2013131 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"634_CR60","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jaut.2018.03.003","volume":"91","author":"T Kraaij","year":"2018","unstructured":"Kraaij, T. et al. The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus. J. Autoimmun. 91, 45\u201354 (2018).","journal-title":"J. Autoimmun."},{"key":"634_CR61","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02631538 (2020)."},{"key":"634_CR62","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1136\/annrheumdis-2018-214720","volume":"78","author":"T D\u00f6rner","year":"2019","unstructured":"D\u00f6rner, T. et al. Treatment of primary Sj\u00f6gren\u2019s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity. Ann. Rheum. Dis. 78, 641\u2013647 (2019).","journal-title":"Ann. Rheum. Dis."},{"issue":"Suppl. 1","key":"634_CR63","first-page":"187","volume":"79","author":"T D\u00f6rner","year":"2020","unstructured":"D\u00f6rner, T. et al. Ianalumab (VAY736), a dual mode of action biologic combining BAFF receptor inhibition with B cell depletion, reaches primary endpoint for treatment of primary Sjogren\u2019s syndrome [abstract OP0302]. Ann. Rheum. Dis. 79 (Suppl. 1), 187\u2013188 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"634_CR64","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04078386 (2021)."},{"key":"634_CR65","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1600-065X.2009.00782.x","volume":"229","author":"R Elgueta","year":"2009","unstructured":"Elgueta, R. et al. Molecular mechanism and function of CD40\/CD40L engagement in the immune system. Immunol. Rev. 229, 152\u2013172 (2009).","journal-title":"Immunol. Rev."},{"key":"634_CR66","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/sji.12121","volume":"79","author":"R Belkhir","year":"2014","unstructured":"Belkhir, R. et al. Upregulation of membrane-bound CD40L on CD4+ T cells in women with primary Sj\u00f6gren\u2019s syndrome. Scand. J. Immunol. 79, 37\u201342 (2014).","journal-title":"Scand. J. Immunol."},{"key":"634_CR67","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.1016\/S2665-9913(19)30135-3","volume":"2","author":"BA Fisher","year":"2020","unstructured":"Fisher, B. A. et al. Assessment of the anti-CD40 antibody iscalimab in patients with primary Sj\u00f6gren\u2019s syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study. Lancet Rheumatol. 2, e142\u2013e152 (2020).","journal-title":"Lancet Rheumatol."},{"key":"634_CR68","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04572841 (2021)."},{"key":"634_CR69","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1084\/jem.191.10.1745","volume":"191","author":"JB Petro","year":"2000","unstructured":"Petro, J. B., Rahman, S. M., Ballard, D. W. & Khan, W. N. Bruton\u2019s tyrosine kinase is required for activation of I\u03baB kinase and nuclear factor \u03baB in response to B cell receptor engagement. J. Exp. Med. 191, 1745\u20131754 (2000).","journal-title":"J. Exp. Med."},{"key":"634_CR70","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang, M. L. et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 369, 507\u2013516 (2013).","journal-title":"N. Engl. J. Med."},{"key":"634_CR71","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/nm.3884","volume":"21","author":"WH Wilson","year":"2015","unstructured":"Wilson, W. H. et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat. Med. 21, 922\u2013926 (2015).","journal-title":"Nat. Med."},{"key":"634_CR72","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1182\/blood-2011-12-397919","volume":"119","author":"LP Kil","year":"2012","unstructured":"Kil, L. P. et al. Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice. Blood 119, 3744\u20133756 (2012).","journal-title":"Blood"},{"key":"634_CR73","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1136\/annrheumdis-2019-216588","volume":"79","author":"E Rivi\u00e8re","year":"2020","unstructured":"Rivi\u00e8re, E. et al. Salivary gland epithelial cells from patients with Sj\u00f6gren\u2019s syndrome induce B-lymphocyte survival and activation. Ann. Rheum. Dis. 79, 1468\u20131477 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"634_CR74","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04035668 (2021)."},{"key":"634_CR75","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","volume":"170","author":"DA Fruman","year":"2017","unstructured":"Fruman, D. A. et al. The PI3K pathway in human disease. Cell 170, 605\u2013635 (2017).","journal-title":"Cell"},{"key":"634_CR76","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa1315226","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman, R. R. et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 370, 997\u20131007 (2014).","journal-title":"N. Engl. J. Med."},{"key":"634_CR77","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","volume":"370","author":"AK Gopal","year":"2014","unstructured":"Gopal, A. K. et al. PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma. N. Engl. J. Med. 370, 1008\u20131018 (2014).","journal-title":"N. Engl. J. Med."},{"key":"634_CR78","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1093\/rheumatology\/keaa410","volume":"60","author":"M Juarez","year":"2021","unstructured":"Juarez, M. et al. A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sj\u00f6gren\u2019s syndrome. Rheumatology 60, 1364\u20131375 (2021).","journal-title":"Rheumatology"},{"key":"634_CR79","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1002\/1529-0131(200111)44:11<2633::AID-ART443>3.0.CO;2-9","volume":"44","author":"N Amft","year":"2001","unstructured":"Amft, N. et al. Ectopic expression of the B cell-attracting chemokine BCA-1 (CXCL13) on endothelial cells and within lymphoid follicles contributes to the establishment of germinal center-like structures in Sj\u00f6gren\u2019s syndrome. Arthritis Rheum. 44, 2633\u20132641 (2001).","journal-title":"Arthritis Rheum."},{"key":"634_CR80","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1002\/art.11311","volume":"48","author":"S Salomonsson","year":"2003","unstructured":"Salomonsson, S. et al. Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sj\u00f6gren\u2019s syndrome. Arthritis Rheum. 48, 3187\u20133201 (2003).","journal-title":"Arthritis Rheum."},{"key":"634_CR81","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/030097400750001752-1","volume":"29","author":"AK Halse","year":"2000","unstructured":"Halse, A. K., Marthinussen, M. C., Wahren-Herlenius, M. & Jonsson, R. Isotype distribution of anti-Ro\/SS-A and anti-La\/SS-B antibodies in plasma and saliva of patients with Sj\u00f6gren\u2019s syndrome. Scand. J. Rheumatol. 29, 13\u201319 (2000).","journal-title":"Scand. J. Rheumatol."},{"key":"634_CR82","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1136\/ard.2010.144782","volume":"70","author":"E Theander","year":"2011","unstructured":"Theander, E. et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sj\u00f6gren\u2019s syndrome. Ann. Rheum. Dis. 70, 1363\u20131368 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"634_CR83","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nri3700","volume":"14","author":"C Pitzalis","year":"2014","unstructured":"Pitzalis, C., Jones, G. W., Bombardieri, M. & Jones, S. A. Ectopic lymphoid-like structures in infection, cancer and autoimmunity. Nat. Rev. Immunol. 14, 447\u2013462 (2014).","journal-title":"Nat. Rev. Immunol."},{"key":"634_CR84","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/art.40513","volume":"70","author":"EW St Clair","year":"2018","unstructured":"St Clair, E. W. et al. Clinical efficacy and safety of baminercept, a lymphotoxin \u03b2 receptor fusion protein, in primary Sj\u00f6gren\u2019s syndrome: results from a phase II randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 70, 1470\u20131480 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"634_CR85","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1146\/annurev-immunol-031210-101400","volume":"29","author":"S Crotty","year":"2011","unstructured":"Crotty, S. Follicular helper CD4 T cells (TFH). Annu. Rev. Immunol. 29, 621\u2013663 (2011).","journal-title":"Annu. Rev. Immunol."},{"key":"634_CR86","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez004","author":"GM Verstappen","year":"2019","unstructured":"Verstappen, G. M., Kroese, F. G. M. & Bootsma, H. T cells in primary Sj\u00f6gren\u2019s syndrome: targets for early intervention. Rheumatology https:\/\/doi.org\/10.1093\/rheumatology\/kez004 (2019).","journal-title":"Rheumatology"},{"issue":"Suppl. 10","key":"634_CR87","first-page":"2417","volume":"71","author":"X Mariette","year":"2019","unstructured":"Mariette, X. et al. A phase 2a study of MEDI5872 (AMG557), a fully human anti-ICOS ligand monoclonal antibody in patients with primary Sj\u00f6gren\u2019s syndrome [abstract]. Arthritis Rheumatol. 71 (Suppl. 10), 2417 (2019).","journal-title":"Arthritis Rheumatol."},{"issue":"Suppl. 2","key":"634_CR88","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1186\/ar1688","volume":"7","author":"EM Ruderman","year":"2005","unstructured":"Ruderman, E. M. & Pope, R. M. The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis. Arthritis Res. Ther. 7 (Suppl. 2), S21\u2013S25 (2005).","journal-title":"Arthritis Res. Ther."},{"key":"634_CR89","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1002\/acr.22052","volume":"65","author":"S Adler","year":"2013","unstructured":"Adler, S. et al. Evaluation of histologic, serologic, and clinical changes in response to abatacept treatment of primary Sj\u00f6gren\u2019s syndrome: a pilot study. Arthritis Care Res. 65, 1862\u20131868 (2013).","journal-title":"Arthritis Care Res."},{"key":"634_CR90","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1136\/annrheumdis-2013-204653","volume":"73","author":"PM Meiners","year":"2014","unstructured":"Meiners, P. M. et al. Abatacept treatment reduces disease activity in early primary Sj\u00f6gren\u2019s syndrome (open-label proof of concept ASAP study). Ann. Rheum. Dis. 73, 1393\u20131396 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"634_CR91","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1016\/S2665-9913(19)30160-2","volume":"2","author":"JF van Nimwegen","year":"2020","unstructured":"van Nimwegen, J. F. et al. Abatacept treatment for patients with early active primary Sj\u00f6gren\u2019s syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study). Lancet Rheumatol. 2, e153\u2013e163 (2020).","journal-title":"Lancet Rheumatol."},{"key":"634_CR92","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1136\/annrheumdis-2020-218599","volume":"80","author":"AN Baer","year":"2020","unstructured":"Baer, A. N. et al. Efficacy and safety of abatacept in active primary Sj\u00f6gren\u2019s syndrome: results of a phase III, randomised, placebo-controlled trial. Ann. Rheum. Dis. 80, 339\u2013348 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"634_CR93","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1002\/art.39204","volume":"67","author":"JC Hall","year":"2015","unstructured":"Hall, J. C. et al. Molecular subsetting of interferon pathways in Sj\u00f6gren\u2019s syndrome. Arthritis Rheumatol. 67, 2437\u20132446 (2015).","journal-title":"Arthritis Rheumatol."},{"issue":"suppl. 1","key":"634_CR94","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1136\/annrheumdis-2020-eular.5743","volume":"79","author":"V Werth","year":"2020","unstructured":"Werth, V. et al. BIIB059, a humanized monoclonal antibody targeting BDCA2 on plasmacytoid dendritic cells (pDC), shows dose-related efficacy in the phase 2 LILAC study in patients (pts) with active cutaneous lupus erythematosus (CLE) [abstract OP0193]. Ann. Rheum. Dis. 79 (Suppl. 1), 120\u2013121 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"634_CR95","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04496960 (2021)."},{"key":"634_CR96","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04093531 (2021)."},{"key":"634_CR97","first-page":"544","volume":"55","author":"C Oni","year":"2016","unstructured":"Oni, C. et al. Eligibility for clinical trials in primary Sj\u00f6gren\u2019s syndrome: lessons from the UK primary\u00a0Sj\u00f6gren\u2019s syndrome registry. Rheumatology 55, 544\u2013552 (2016).","journal-title":"Rheumatology"},{"key":"634_CR98","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0133907","volume":"10","author":"V Devauchelle-Pensec","year":"2015","unstructured":"Devauchelle-Pensec, V. et al. Which and how many patients should be included in randomised controlled trials to demonstrate the efficacy of biologics in primary Sj\u00f6gren\u2019s syndrome? PLoS ONE 10, e0133907 (2015).","journal-title":"PLoS ONE"},{"issue":"Suppl. 10","key":"634_CR99","first-page":"1502","volume":"72","author":"S Arends","year":"2020","unstructured":"Arends, S. et al. Composite of relevant endpoints for Sj\u00f6gren\u2019s syndrome (CRESS) [abstract]. Arthritis Rheumatol. 72 (Suppl. 10), 1502 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"634_CR100","unstructured":"European Medicines Agency. EU Clinical Trials Register https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2014-003140-12\/NL (2015)."},{"key":"634_CR101","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01782235 (2019)."},{"key":"634_CR102","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02149420 (2019)."},{"key":"634_CR103","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02291029 (2021)."},{"key":"634_CR104","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03905525 (2021)."},{"key":"634_CR105","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02610543 (2020)."},{"key":"634_CR106","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02334306 (2019)."},{"key":"634_CR107","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02067910 (2019)."},{"key":"634_CR108","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02915159 (2020)."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41584-021-00634-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41584-021-00634-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41584-021-00634-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T18:23:20Z","timestamp":1684607000000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-021-00634-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,29]]},"references-count":108,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["634"],"URL":"https:\/\/doi.org\/10.1038\/s41584-021-00634-x","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,29]]},"assertion":[{"value":"11 May 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.S. declares that she has received honorarium from BMS, Pfizer and UCB. G.N. declares that she has received honorarium from Lilly, Novartis and UCB. X.M. declares that he has received honorarium from BMS, Galapagos, Gilead, GSK, Novartis, Pfizer, Servier and UCB. X.M. has also received an unrelated research grant from OSE Immunotherapeutics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}